<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>R-CODOX-M/IVAC (Magrath) regimen for Burkitt lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">R-CODOX-M/IVAC (Magrath) regimen for Burkitt lymphoma</h1>
<div class="graphic"><div class="figure"><div class="ttl">R-CODOX-M/IVAC (Magrath) regimen for Burkitt lymphoma</div><div class="cntnt"><table cellspacing="0"><tbody> <tr class="border_bottom_thick"> <td>The R-CODOX-M/IVAC regimen is composed of four cycles, each cycle lasting until the absolute neutrophil count returns to &gt;1000/microL and the platelet count &gt;100,000/microL. Cycles 1 and 3 are R-CODOX-M and cycles 2 and 4 are R-IVAC. Three cycles of R-CODOX-M are sufficient for patients with low-risk disease (ie, a single focus of disease &lt;10 cm in diameter and a normal serum lactate dehydrogenase level).</td> </tr> <tr> <td class="subtitle1_single">R-CODOX-M <span style="white-space: nowrap;">(cycles 1 and 3):<sup>[1-4]</sup></span></td> </tr> <tr> <td class="indent1">Rituximab 375 mg/m<sup>2</sup> IV on day 1</td> </tr> <tr> <td class="indent1">Cyclophosphamide 800 mg/m<sup>2</sup> IV on day 1</td> </tr> <tr> <td class="indent1">Cyclophosphamide 200 mg/m<sup>2</sup> IV on days 2 through 5</td> </tr> <tr> <td class="indent1">Doxorubicin 40 mg/m<sup>2</sup> slow IV push on day 1</td> </tr> <tr> <td class="indent1">Vincristine 1.5 mg/m<sup>2</sup> (maximum 2 mg) IV on days 1 and 8 (cycle 1) and days 1 and 8 (cycle 3)</td> </tr> <tr> <td class="indent1">Methotrexate</td> </tr> <tr> <td class="indent2"> <ul> <li>Age 65 years or younger: 300 mg/m<sup>2</sup> IV loading dose over one hour on day 10, followed by 2700 mg/m<sup>2</sup> IV infusion administered over the next 23 hours; leucovorin rescue begins 36 hours from the start of the methotrexate infusion</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Age &gt;65 years: 100 mg/m<sup>2</sup> IV loading dose over one hour on day 10, followed by 900 mg/m<sup>2</sup> IV infusion administered over the next 23 hours; leucovorin rescue begins 36 hours from the start of the methotrexate infusion</li> </ul> </td> </tr> <tr> <td class="indent1">Granulocyte colony stimulating factor begins 24 hours after leucovorin rescue is started and continues until the absolute neutrophil count is &gt;1000/microL</td> </tr> <tr> <td class="indent1">Intrathecal medications</td> </tr> <tr> <td class="indent2"> <ul> <li>Intrathecal cytarabine 70 mg (if &gt;3 years of age) on days 1 and 3</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Intrathecal methotrexate 12 mg (if &gt;3 years of age) on day 15</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Oral leucovorin 15 mg/dose on day 16, 24 hours after intrathecal methotrexate</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Enhanced CNS-directed therapy for patients with CNS disease at presentation: cytarabine 70 mg/dose (if &gt;3 years of age) intrathecal (or 15 mg if via Ommaya reservoir) on day 5 and methotrexate 12 mg (if &gt;3 years of age) intrathecal (or 2 mg if via Ommaya reservoir) on day 17 in <span style="white-space: nowrap;">cycle 1<sup>[2]</sup></span></li> </ul> </td> </tr> <tr> <td class="subtitle1_single">R-IVAC <span style="white-space: nowrap;">(cycles 2 and 4):<sup>[1-4]</sup></span></td> </tr> <tr> <td class="indent1">Rituximab 375 mg/m<sup>2</sup> IV on day 1</td> </tr> <tr> <td class="indent1">Ifosfamide</td> </tr> <tr> <td class="indent2"> <ul> <li>Age 65 years or younger: 1500 mg/m<sup>2</sup> IV on days 1 through 5 with mesna uroprotection</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Age &gt;65 years: 1000 mg/m<sup>2</sup> IV on days 1 through 5 with mesna uroprotection</li> </ul> </td> </tr> <tr> <td class="indent1">Etoposide 60 mg/m<sup>2</sup> IV on days 1 through 5</td> </tr> <tr> <td class="indent1">Cytarabine</td> </tr> <tr> <td class="indent2"> <ul> <li>Age 65 years or younger: 2 g/m<sup>2</sup> IV every 12 hours on days 1 and 2 (four doses)</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Age &gt;65 years: 1 g/m<sup>2</sup> IV every 12 hours on days 1 and 2 (four doses)</li> </ul> </td> </tr> <tr> <td class="indent1">Granulocyte colony stimulating factor begins 24 hours after the completion of IV chemotherapy and continues until the absolute neutrophil count is &gt;1000/microL</td> </tr> <tr> <td class="indent1">Intrathecal medications</td> </tr> <tr> <td class="indent2"> <ul> <li>Intrathecal methotrexate 12 mg (if &gt;3 years of age) on day 5</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Oral leucovorin 15 mg on day 6, 24 hours after intrathecal methotrexate</li> </ul> </td> </tr> <tr> <td class="indent2"> <ul> <li>Enhanced CNS-directed therapy for patients with CNS disease at presentation: cytarabine 70 mg (if &gt;3 years of age) intrathecal (or 15 mg if via Ommaya reservoir) on days 7 and 9 in <span style="white-space: nowrap;">cycle 2<sup>[2]</sup></span></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table illustrates the R-CODOX-M/IVAC (Magrath) regimen used for aggressive lymphomas. The version used in the earliest clinical trial included a cycle 3, day 15 dose of vincristine, which has been eliminated from most subsequent trials investigating this regimen.</div><div class="graphic_footnotes">IV: intravenous; CNS: central nervous system.</div><div class="graphic_reference">References:
<ol>
<li>Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14:925.</li>
<li>Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 Study. Ann Oncol 2002; 13:1264.</li>
<li>Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 Trial). Blood 2008; 112:2248.</li>
<li>Lacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004; 45:761.</li>
</ol></div><div id="graphicVersion">Graphic 72511 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
